These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

868 related articles for article (PubMed ID: 9839089)

  • 1. Inhibition and induction of cytochrome P450 and the clinical implications.
    Lin JH; Lu AY
    Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A.
    Lin PP; Li XN; Yuan F; Chen WL; Yang MJ; Xu HR
    Biochem Biophys Res Commun; 2016 Nov; 480(2):248-253. PubMed ID: 27751854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
    VandenBrink BM; Isoherranen N
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):66-77. PubMed ID: 20047147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes.
    Tanaka E
    J Clin Pharm Ther; 1998 Dec; 23(6):403-16. PubMed ID: 10048501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.
    Bertz RJ; Granneman GR
    Clin Pharmacokinet; 1997 Mar; 32(3):210-58. PubMed ID: 9084960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors.
    Naritomi Y; Teramura Y; Terashita S; Kagayama A
    Drug Metab Pharmacokinet; 2004 Feb; 19(1):55-61. PubMed ID: 15499170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
    Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review).
    Murray M
    Int J Mol Med; 1999 Mar; 3(3):227-38. PubMed ID: 10028046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
    Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
    Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450-mediated metabolism in the human gut wall.
    Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data.
    Walker DK; Alabaster CT; Congrave GS; Hargreaves MB; Hyland R; Jones BC; Reed LJ; Smith DA
    Drug Metab Dispos; 1996 Apr; 24(4):447-55. PubMed ID: 8801060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.
    Donato MT; Castell JV
    Clin Pharmacokinet; 2003; 42(2):153-78. PubMed ID: 12537515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
    Manikandan P; Nagini S
    Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450s in the development of target-based anticancer drugs.
    Purnapatre K; Khattar SK; Saini KS
    Cancer Lett; 2008 Jan; 259(1):1-15. PubMed ID: 18053638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
    Fontana E; Dansette PM; Poli SM
    Curr Drug Metab; 2005 Oct; 6(5):413-54. PubMed ID: 16248836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme kinetics for clinically relevant CYP inhibition.
    Zhang ZY; Wong YN
    Curr Drug Metab; 2005 Jun; 6(3):241-57. PubMed ID: 15975042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of herbs with cytochrome P450.
    Zhou S; Gao Y; Jiang W; Huang M; Xu A; Paxton JW
    Drug Metab Rev; 2003 Feb; 35(1):35-98. PubMed ID: 12635815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
    Kumar G; Lau H; Laskin O
    Cancer Chemother Pharmacol; 2009 May; 63(6):1171-5. PubMed ID: 19030860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition.
    Zheng YF; Bae SH; Choi EJ; Park JB; Kim SO; Jang MJ; Park GH; Shin WG; Oh E; Bae SK
    Food Chem Toxicol; 2014 Jun; 68():117-27. PubMed ID: 24632066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.